Mesoblast’s MPC therapy trial reports better cardioprotective effect
Under the trial, Mesoblast carried out a post-hoc analysis in 30 patients who were randomized to receive either placebo or a single administration of 150 million MPCs (MPC-150-IM).
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
In August, NYBC announced a partnership with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for the repair and